#United States #New York #mental health #GrayMatters Health #Prism Suite

GrayMatters Health Expands Mental Health Solutions with Prism™ Suite

GrayMatters Health (GMH) has made a significant advancement in mental health treatment by launching the Prism™ Suite, a new portfolio of solutions designed to improve patient outcomes and empower healthcare providers. This innovative suite builds upon GMH's groundbreaking work in the field of digital brain biomarkers, having previously introduced the FDA-cleared Prism™ for PTSD.

The latest addition to the Prism™ Suite is a protocol specifically tailored for patients suffering from depression. This new feature aims to broaden GMH's impact on mental health care by integrating advanced technology that utilizes the world’s first fMRI-informed digital biomarkers. The suite is expected to revolutionize the way mental health providers guide and support patients on their recovery journey.

Understood as a method to enhance brain activity regulation, the Depression protocol utilizes a reward-system biomarker, allowing patients to learn and practice self-regulation techniques in a structured manner. Dr. Linda Carpenter, a respected authority in psychiatry at Brown University, has expressed enthusiasm about this novel approach, recognizing its potential to connect directly with brain systems pertinent to mood regulation. She noted that this targeted methodology could serve as a bespoke care option tailored for individuals with depression, especially those struggling with anhedonia.

In engaging interactive sessions, patients will utilize the Prism™ platform to explore mental strategies that amplify their reward-system biomarker levels. The encouraging results from the initial pilot study, which were shared in the journal Brain Sciences, indicated that nearly 78% of participants experienced a reduction in depressive symptoms while demonstrating significant improvements in anhedonia.

Oded Kraft, CEO and co-founder of GrayMatters Health, highlighted the transformative potential of the platform: "By incorporating the Depression protocol, we are not only enriching our suite of services but also ensuring that more patients have access to a personalized therapeutic experience that can be integrated into their daily lives. Our aim is to harness the power of brain science to equip mental healthcare providers with effective tools that facilitate real progress for their patients."

In addition to enhancing the patient experience, the Prism™ Suite includes robust features for healthcare providers, enabling them to assess patient progress effectively. The Insights tool offers data-driven analytics, providing valuable feedback regarding patient performance and suggested discussion topics to enrich their experience with the Prism™ technology.

At the core of GMH’s innovative solutions is its proprietary EEG-fMRI-Pattern (EFP) digital biomarkers, which leverage advanced machine learning to map high-resolution fMRI data from deep within the brain onto EEG signals. The company's award-winning treatment for PTSD is currently making a difference in clinics across various states including California, Connecticut, Florida, Georgia, Illinois, Massachusetts, New York, North Dakota, Pennsylvania, Rhode Island, Texas, and Washington.

For those interested in discovering more about Prism™ and its capabilities, further information is available on GMH's official website at GrayMatters Health.

About GrayMatters Health
GrayMatters Health is at the forefront of mental health technology, offering interventional psychiatry solutions driven by digital fMRI-informed biomarkers. The Prism™ platform promotes self-neuromodulation, enabling patients to cultivate personalized mental strategies aimed at regulating brain activity related to their conditions, both in clinical settings and their everyday lives.

GMH is actively collaborating with leading mental health institutions to conduct research and evaluate the Prism™ platform for various other psychiatric disorders. The foundational technology of GMH has undergone extensive scrutiny and is featured in numerous peer-reviewed publications, spearheaded by Professor Talma Hendler and her research team at Tel Aviv University.

For ongoing updates and information, you can follow GrayMatters Health on LinkedIn.